Literature DB >> 16289903

Increasing incidence of mumps in Scotland: options for reducing transmission.

Martin Donaghy1, J Claire Cameron, Vera Friederichs.   

Abstract

BACKGROUND: There has been a dramatic increase in mumps in Scotland since November 2003, with cases primarily in adolescents and young adults.
OBJECTIVES: This paper describes mumps epidemiology in Scotland, undertakes a risk assessment and considers option for reducing transmission.
RESULTS: Mumps is primarily a risk for the 13-25 year age group, as they have neither been offered two routine doses of measles, mumps and rubella MMR vaccine, nor been exposed to wild virus. Transmission is facilitated by a high degree of social mixing, with enclosed settings (school, universities etc.) being higher risk. On the basis of susceptibility and risk of transmission, three categories of higher (17-20 years), intermediate (21-22; 15-16 years), and low (23-25; 13-14 years) risk were defined, all in higher risk enclosed settings. Herd immunity would be very difficult to achieve, as it would require unrealistically high MMR uptake (an additional 45-80% in 17-20 year olds). A risk management strategy of reducing transmission and decreasing the likelihood of outbreaks was therefore proposed. Action would be targeted at the higher risk group (17-20 years) in higher risk settings. Three options were considered: do nothing; opportunistic immunisation through GPs; a mass campaign. The 'do nothing' option was discounted. The preferred option was to alert GPs to the need to offer MMR vaccine to 17-20 year olds in higher risk settings. The rationale for this was that it had the lowest cost, avoided disruption to services, and primarily that it would reduce the probability of mumps transmission in higher risk settings.
CONCLUSIONS: The Chief Medical Officer issued a letter to all health professionals in Scotland encouraging them to offer MMR vaccine to 13-15 year olds, who had not previously received two doses, and particularly those aged 17-20 years in higher risk settings.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16289903     DOI: 10.1016/j.jcv.2005.09.009

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  4 in total

1.  Prevalence of mumps antibodies in the Israeli population in relation to mumps vaccination policy and incidence of disease.

Authors:  Kh Muhsen; Y Aboudy; E Mendelson; M S Green; D Cohen
Journal:  Epidemiol Infect       Date:  2007-07-03       Impact factor: 2.451

2.  An outbreak of mumps with genetic strain variation in a highly vaccinated student population in Scotland.

Authors:  L J Willocks; D Guerendiain; H I Austin; K E Morrison; R L Cameron; K E Templeton; V R F DE Lima; R Ewing; W Donovan; K G J Pollock
Journal:  Epidemiol Infect       Date:  2017-09-14       Impact factor: 4.434

Review 3.  Dissecting the indirect effects caused by vaccines into the basic elements.

Authors:  Carla D Scarbrough Lefebvre; Augustin Terlinden; Baudouin Standaert
Journal:  Hum Vaccin Immunother       Date:  2015-07-17       Impact factor: 3.452

4.  Waning Immunity Is Associated with Periodic Large Outbreaks of Mumps: A Mathematical Modeling Study of Scottish Data.

Authors:  Dalila Hamami; Ross Cameron; Kevin G Pollock; Carron Shankland
Journal:  Front Physiol       Date:  2017-04-25       Impact factor: 4.566

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.